Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). by Di Carlo, Veronica et al.
Trends in short-term survival from distant-stage cutaneous melanoma
in the United States, 2001-2013 (CONCORD-3)
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Abstract
Background: Survival from metastatic cutaneous melanoma is substantially lower than for localized disease. Treatments for
metastatic melanoma have been limited, but remarkable clinical improvements have been reported in clinical trials in the
last decade. We described the characteristics of US patients diagnosed with cutaneous melanoma during 2001-2013 and
assessed trends in short-term survival for distant-stage disease. Methods: Trends in 1-year net survival were estimated using
the Pohar Perme estimator, controlling for background mortality with life tables of all-cause mortality rates by county of resi-
dence, single year of age, sex, and race for each year 2001-2013. We fitted a flexible parametric survival model on the log-
hazard scale to estimate the effect of race on the hazard of death because of melanoma and estimated 1-year net survival by
race. Results: Only 4.4% of the 425 915 melanomas were diagnosed at a distant stage, cases diagnosed at a distant stage are
more commonly men, older patients, and African Americans. Age-standardized, 1-year net survival for distant-stage disease
was stable at approximately 43% during 2001-2010. From 2010 onward, survival improved rapidly, reaching 58.9% (95% confi-
dence interval ¼ 56.6% to 61.2%) for patients diagnosed in 2013. Younger patients experienced the largest improvement.
Survival for distant-stage disease increased in both Blacks and Whites but was consistently lower in Blacks. Conclusions:
One-year survival for distant-stage melanoma improved during 2001-2013, particularly in younger patients and those diag-
nosed since 2010. This improvement may be a consequence of the introduction of immune-checkpoint-inhibitors and other
targeted treatments for metastatic and unresectable disease. Persistent survival inequalities exist between Blacks and
Whites, suggesting differential access to treatment.
The incidence of cutaneous melanoma has been rising in most
Caucasian populations during the past 50 years (1). In the
United States, the age-standardized incidence rate rose from
8 per 100 000 person-years in 1975 to 25 in 2016 (2). Cutaneous
melanoma was the fourth and fifth most common cancer in
men and women, respectively, in the United States in 2016,
with a total of 82 476 new cases (3).
The third cycle of the CONCORD programme for the global
surveillance of cancer survival (CONCORD-3) highlighted increas-
ing trends in age-standardized 5-year net survival from
cutaneous melanoma in most countries during 2000-2014; 5-year
net survival exceeded 90% for patients diagnosed during 2010-
2014 in the United States, Australia, New Zealand, and most
Nordic and Western European countries but was below 60% in
Ecuador, China, and Taiwan (4). Stage at diagnosis is an
important predictor of prognosis, and survival for disease
diagnosed at an advanced stage is much lower than for localized
disease. If detected at a localized stage (tumor node metastasis
[TNM] stage I-II and resectable stage III), cutaneous melanoma
can be surgically treated with a favorable outcome. Five-year
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relative survival for localized melanoma of the skin diagnosed in
the last 20 years was higher than 90% in Germany (5), Denmark
(6), Estonia (7), Sweden (8), and the United States (9).
Until about 2010, when advanced disease (TNM stage III
unresectable melanoma and stage IV disease) was mainly
treated with chemotherapy (eg, dacarbazine) and cytokines (eg,
interleukin-2), the prognosis for metastatic melanoma was gen-
erally poor, with survival as low as 16% at 5 years after diagnosis
for patients diagnosed in the United States (9,10). In recent
years, major improvements in treatment, involving the use of
targeted therapies and immunotherapy, have led to unprece-
dented clinical benefit. Ipilimumab, the first immunotherapy,
and vemurafenib, the first targeted treatment for metastatic
and unresectable melanoma, were approved by the US Food
and Drug Administration (FDA) in 2011.
The aim of this study is to describe the characteristics of
patients diagnosed with cutaneous melanoma during 2001-2013
using data provided by 34 US population-based cancer registries
included in CONCORD-3 and to assess trends in short-term (1-
year) survival for distant-stage disease.
Methods
CONCORD-3 obtained anonymized, individual tumor records
from 322 population-based cancer registries in 71 countries
worldwide, for patients who had been diagnosed with one of 18
common cancers, including melanoma, during 2000-2014 and
followed-up to December 31, 2014. Data acquisition, ethical ap-
proval, and data quality control for the CONCORD programme
have been described elsewhere (4). Cancer registries submitted
records on all patients diagnosed with a melanoma, defined by
morphology codes in the range 8720-8790 in the International
Classification of Diseases for Oncology, third revision (ICD-O-3)
(11). We restricted survival analysis to malignant melanoma
(ICD-O-3 behavior code 3) arising in the skin (ICD-O-3 topogra-
phy codes C44.0-C44.9), including the skin of the labia majora
(C51.0), vulva (C51.9), penis (C60.9), and scrotum (C63.2).
Records with incomplete data or for tumors that were be-
nign, in situ, of uncertain behavior, metastatic from another or-
gan, or unknown if primary or metastatic, or on patients with
age outside the range 15-99 years, were considered ineligible for
analysis.
We excluded tumors registered only from a death certificate
or discovered at autopsy, because their duration of survival was
unknown, as well as records for which the vital status or sex
was unknown and those with an invalid date or sequence of
dates.
We included in analysis only primary, invasive, malignant
cutaneous melanoma. If two or more invasive primary malig-
nant melanomas were detected in the same person but with dif-
ferent dates of diagnosis, the record with the earliest date of
diagnosis was retained. Registry datasets in which 15.0% or
more of patients were lost to follow-up were excluded from the
survival analyses.
Patients diagnosed in 2014 were included in CONCORD-3 but
were not included in this study, because a full year of follow-up
was not available by the study closure date (December 31, 2014).
To assess trends in survival for the same registries, we retained
only registries that submitted data on patients diagnosed up to
and including 2013, with follow-up to December 31, 2014.
The CONCORD protocol required information on stage of dis-
ease at the time of diagnosis for patients diagnosed from 2001
onward, because the completeness of data on stage in many
countries and United States was known to be much lower before
2001.
Stage was categorized as localized, regional, and distant
according to the Surveillance, Epidemiology, and End Results
Summary Stage 2000 classification (12). “Distant stage” includes
melanoma with distant lymph node involvement, metastatic
skin lesions, further contiguous extension, or metastasis to
other organs. Age at diagnosis was grouped into 15-44 years, 45-
54 years, 55-64 years, 65-74 years, and 75-99 years. Race was cat-
egorized as White, Black, and other race or ethnicities (Asian or
Pacific Islander; American Indian or Alaska Native; other,
unspecified or unknown race).
Melanomas were defined by morphology (ICD-O-3 8720–
8790). We selected melanomas of the skin on the basis of topo-
graphic codes C44.0-C44.9 (skin), C51.0 (including the skin of the
labia majora), C51.9 (vulva), C60.9 (penis), or C63.2 (scrotum).
Melanomas were further categorized by anatomic subsite as
arising in the skin of the head and neck (C44.0-C44.4), the trunk
(C44.5), the limbs (C44.6-C44.7), or the genital organs (C51.0,
C51.9, C60.9, C63.2), as lesions overlapping 2 of those categories,
or of the skin with anatomic location not otherwise specified
(C44.8-C44.9). Histological subtypes were grouped according to
the first revision of ICD-O-3 (11) as malignant melanoma, not
otherwise specified (NOS, 8720), superficial spreading (8743),
lentigo maligna (8742), nodular (8721), acral (8744), and all other
morphologies (8722-8723, 8726-8727, 8730, 8740-8741, 8743,
8745-8746, 8750, 8760-8761, 8770-8774, 8780, 8790).
We explored the distribution of stage at diagnosis by sex,
age, race, topography, and morphology. Survival analyses were
restricted to patients diagnosed with distant-stage melanoma.
One-year net survival for patients diagnosed in each of the
13 years from 2001 to 2013 was estimated with the non-para-
metric Pohar Perme estimator (13) using the STATA (14) com-
mand stns (15). Net survival is the cumulative probability that
cancer patients survive their cancer up to a given time since di-
agnosis (eg, 1 year) after correcting for other causes of death
(background mortality). To control for background mortality,
which varies by geographical area, demographic characteristics,
and over time, we used life tables of all-cause mortality in the
general population by single year of age, sex, single calendar
year, race (Blacks, Whites, and others) and county within each
state. These life tables were kindly provided by the National
Cancer Institute (16).
We estimated trends in 1-year net survival for 5 age groups.
We then obtained age-standardized estimates for all ages com-
bined using the second of the 3 sets of International Cancer
Survival Standard weights (0.28, 0.17, 0.21, 0.20, and 0.14)
designed for cancers with broadly constant incidence by age
(17). Survival was estimated for men and women, and for both
sexes combined.
We fitted a flexible parametric survival model on the log-
hazard scale to estimate the effect of race on the hazard of
death because of distant-stage melanoma; excess mortality and
net survival by race were also estimated (18), with race as a cat-
egorical variable. Restricted cubic splines for the effect of age at
diagnosis (3 degrees of freedom) and year of diagnosis (4
degrees of freedom) were included with the command rcsgen
(19), including time-dependent effects.
Results
The CONCORD database included individual records for
1 040 814 adults (15-99 years) diagnosed with a primary,
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malignant cutaneous melanoma in 41 state-wide cancer regis-
tries in the United States covering a total population of 257 mil-
lion people (80.2% of the US population). Data quality was
generally high. The proportion of patients excluded for incom-
plete dates or for other reasons ranged from 0.0% to 4.4%
(Table 1). Overall, 36.0% of patients were diagnosed with an in
situ tumor.
Of the 632 861 patients eligible for inclusion in survival anal-
yses, we excluded 3045 (0.5%) because the cancer was registered
only from a death certificate or discovered at autopsy; survival
time for these patients is unknown. Only 2.7% of the remaining
629 816 patients were lost to follow-up or censored within
5 years from diagnosis, but this proportion was much lower
among patients with distant-stage disease (0.3%). The diagnosis
was histologically confirmed in 99.3% of tumors (data not
shown).
New Jersey was excluded because of the high proportion of
patients lost to follow-up (48.2%). A further 118 239 patients
were excluded from 6 state-wide registries (Arkansas,
California, Massachusetts, Oklahoma, Tennessee, and


















situ Other DCO Other
Lost to
follow-up Censored
All US registries 2000-2014 1 040 814 0.6 36.0 2.6 632 861 0.5 0.0 629 816 2.6 0.1
Alabama 2000-2014 23 564 0.9 41.3 2.3 13 084 0.6 0.0 13 012 0.0 0.0
Alaska 2000-2013 1533 4.4 30.6 3.5 944 0.4 0.0 940 0.0 0.0
Arkansas 2000-2011 7592 0.3 31.9 3.3 4897 0.3 0.0 4879 0.0 0.0
California 2000-2011 127 043 1.1 36.9 2.3 75 851 0.2 0.0 75 712 0.0 0.0
Colorado 2000-2013 21 135 0.3 33.1 3.1 13 427 0.7 0.0 13 338 0.0 0.0
Connecticut 2000-2014 21 602 0.4 40.9 2.2 12 211 0.2 0.0 12 185 5.5 0.0
Delaware 2000-2014 6283 0.2 44.0 1.4 3413 0.2 0.0 3406 0.0 0.0
Florida 2000-2013 89 847 0.1 35.4 2.7 55 590 0.7 0.1 55 134 0.0 0.0
Georgia 2000-2014 43 981 0.0 35.6 2.0 27 451 0.4 0.0 27 350 0.0 0.0
Hawaii 2000-2014 5753 0.3 33.7 1.5 3710 0.2 0.0 3704 7.5 0.0
Idaho 2000-2014 9032 0.6 40.8 2.2 5095 0.7 0.0 5059 0.0 0.0
Indiana 2000-2014 25 599 0.6 32.3 3.3 16 347 0.5 0.0 16 269 0.0 0.0
Iowa 2000-2014 15 612 0.6 32.6 3.7 9846 0.2 0.0 9822 2.8 0.0
Kentucky 2000-2014 23 097 0.0 33.3 2.8 14 764 0.2 0.0 14 729 6.4 0.0
Louisiana 2000-2014 15 105 0.5 37.1 2.8 9000 0.2 0.0 8982 6.4 0.1
Maine 2000-2013 7860 0.3 38.4 3.0 4581 0.3 0.0 4565 0.0 0.0
Maryland 2000-2014 29 516 0.4 40.2 1.8 16 981 0.6 0.1 16 868 0.0 0.0
Massachusetts 2000-2009 23 194 0.0 34.5 3.0 14 483 0.4 0.0 14 420 0.0 0.0
Michigan 2000-2013 41 986 0.2 36.5 2.5 25 505 0.6 0.0 25 335 0.0 0.0
Minnesota 2000-2013 27 449 0.0 38.1 1.9 16 472 0.3 0.0 16 421 0.0 0.0
Mississippi 2002-2014 9214 0.8 31.6 2.8 5968 0.6 0.0 5931 0.0 0.0
Montana 2000-2014 5595 0.6 37.8 2.9 3289 0.5 0.0 3272 0.0 0.0
Nebraska 2000-2014 7894 0.6 33.4 3.5 4930 0.5 0.0 4906 0.0 0.0
New Hampshire 2000-2014 9727 0.1 40.3 2.3 5575 0.3 0.0 5560 0.0 0.0
New Jersey 2000-2014 49568 0.8 42.7 1.9 27 024 0.4 0.0 26 910 48.2 0.0
New Mexico 2000-2014 8720 0.0 40.1 2.2 5030 0.6 0.0 5000 8.7 0.4
North Carolina 2000-2014 47 654 0.0 39.5 2.4 27 727 0.4 0.0 27 602 0.0 0.0
Ohio 2000-2014 54 382 0.1 35.7 3.0 33 292 0.6 0.0 33 079 0.0 0.0
Oklahoma 2000-2010 9135 0.4 24.8 3.9 6479 1.1 0.0 6407 0.0 0.0
Oregon 2000-2013 24 301 0.1 40.9 2.6 13 703 0.5 0.0 13 637 0.0 0.0
Pennsylvania 2000-2014 62 912 2.4 32.9 2.7 39 052 0.4 0.0 38 904 0.0 0.0
Rhode Island 2000-2014 6363 0.4 39.0 2.4 3703 0.4 0.0 3688 0.0 0.0
South Carolina 2000-2014 24 940 0.0 40.8 1.8 14 309 0.5 0.0 14 230 0.0 0.0
Tennessee 2000-2011 19 264 0.5 28.5 3.3 13 047 0.3 0.0 13 003 0.0 0.0
Texas 2000-2013 59 374 0.9 28.4 3.5 39 862 0.8 0.0 39 555 0.0 0.0
Utah 2000-2014 14 946 0.1 38.2 2.1 8893 0.1 0.0 8885 0.0 0.2
Vermont 2000-2013 4537 0.1 38.8 1.9 2688 0.3 0.0 2679 0.0 0.0
Washington 2000-2008 22 317 0.8 39.2 2.2 12 876 0.2 0.0 12 843 0.0 0.0
West Virginia 2000-2014 8894 1.3 31.1 3.4 5707 0.4 0.0 5682 0.0 0.0
Wisconsin 2000-2013 21 636 0.9 28.4 3.6 14 507 1.0 0.0 14 366 0.0 0.0
Wyoming 2000-2013 2658 0.2 38.6 2.9 1548 0.1 0.0 1547 0.0 0.1
aIncomplete dates: records in which the year of birth is unknown, the month and/or year of diagnosis is unknown, or the year of last known vital status is unknown.
Other: records with incomplete data or for tumors that are benign (behavior code 0), of uncertain behavior (1), metastatic from another organ (6), or unknown if primary
or metastatic (9); or for patients with age outside the range of 15-99 years. DCO ¼ Tumours registered only from a death certificate.
bOther: vital status or sex unknown; invalid date or sequence of dates.
cCensored: patients whose last known vital status is “alive” and who were censored within 5 years of diagnosis or, if diagnosed in 2010 or later, before December 31,
2014.
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Washington), because data were not available for patients diag-
nosed up to and including 2013. Finally, we explored the distri-
bution of 425 915 patients by sex, age, race, topography,
morphology, and stage at diagnosis.
Most patients diagnosed during 2001-2013 were men (56.8%),
and they were generally older than women (median age at diag-
nosis ¼ 64 vs 57 years, respectively). Only 0.6% of patients were
Black (Table 2). Data on stage at diagnosis were available for
386 885 (90.8%) patients.
A majority of patients (77.1%) were diagnosed with localized
disease. This proportion was stable over time (76.4%-79.8%, data
not shown) and slightly higher in women (79.3% vs 75.3%) and
in younger patients (79.7% vs 74.1% in patients aged 15-44 years
and 75-99 years, respectively). Of melanomas, 4.4% were diag-
nosed at a distant stage, with a slightly higher proportion in
men than women (4.6% vs 2.8% respectively, in 2001; 6.2% vs
4.5% in 2013, data not shown). There were 14.6% of Blacks diag-
nosed with distant-stage disease compared with only 4.4% in
Whites and 1.2% in the “other race” category. Patients with
distant-stage melanoma were generally older (median age ¼
65 years) than those diagnosed with localized (61 years) or re-
gional (62 years) disease (data not shown).
Melanomas arose mostly on the skin of the limbs (42.1%),
the trunk (32.1%), and the head and neck (20.6%) and were diag-
nosed at a distant stage in 2.0% of those cases (Table 2).
Melanomas arising in overlapping or unspecified locations
accounted for only 4.9% of all cases, but about one-half of these
(49.6%) were diagnosed at an advanced stage. The proportion of
melanomas registered with an unspecified morphology was
51.9%, followed by superficial spreading (29.8%) and nodular
melanoma (7.2%). Distant-stage melanomas represented less
than 1% of the superficial spreading and lentigo maligna mor-
phologies (0.8% and 0.6%, respectively), but up to 6.7% of those
classified as malignant melanoma NOS.
We restricted survival analysis to 18 601 patients diagnosed
with distant-stage disease (Figure 1). In 2001, age-standardized
1-year net survival was 42.8% (95% confidence interval [CI] ¼
39.3% to 46.3%) and remained stable until 2010 (Table 3).
Survival improved rapidly from 2010 onward, reaching 58.9%
(95% CI ¼ 56.6% to 61.2%) for patients diagnosed in 2013. The
trend was similar for men and women, although survival was
slightly but consistently higher in women (Table 3).
One-year net survival increased for all ages (Figure 2;
Table 3). The youngest patients (15-44 years) experienced the
largest absolute improvement, particularly from 2010, increas-
ing from 44.4% (95% CI ¼ 35.9% to 52.8%) in 2001 to 67.8% (95% CI
¼ 62.0% to 73.6%) in 2013. For patients aged 45-54 years, 1-year
survival increased from 45.7% (95% CI ¼ 38.4% to 53.1%) in 2001
to 62.7% (95% CI ¼ 57.6% to 67.8%) in 2013. We observed similar
trends in patients aged 55-64 years and 65-74 years starting
from 2011; both survival curves reached 56% (56.1%, 95% CI ¼
51.6% to 60.6%; and 56.7%, 95% CI ¼ 52.4% to 60.9%, respectively)
in 2013. One-year survival for patients aged 75 years or older
remained at 44.5% (95% CI ¼ 39.9% to 49.1%) or lower throughout
the period 2001-2013.
Age-standardized 1-year net survival increased for both
Whites and Blacks with distant-stage melanoma (Figure 3).
Survival for Whites increased from 42.3% (95% CI ¼ 39.9% to
Table 2. Adults (15-99 years) diagnosed with primary malignant melanoma of the skin during 2001-2013 in 34 US registries: distribution by sex,
age at diagnosis, race, anatomic location, morphology, and SEER Summary Stage 2000a
Patient and tumor characteristics
Localized Regional Distant Unknown Total
No. (%) No. (%) No. (%) No. (%) No. (%)
Sex
Male 182 150 (75.3) 24 747 (10.2) 12 443 (5.1) 22 470 (9.4) 241 810 (56.8)
Female 146 022 (79.3) 15 365 (8.3) 6158 (3.3) 16 560 (9.1) 184 105 (43.2)
Age group, y
15-44 61 321 (79.7) 7039 (9.1) 2074 (2.7) 6510 (8.5) 76 944 (18.1)
45-54 58 041 (78.2) 6857 (9.2) 2942 (4.0) 6386 (8.6) 74 226 (17.4)
55-64 69 434 (77.4) 8296 (9.2) 4131 (4.6) 7848 (8.8) 89 709 (21.1)
65-74 66 251 (76.8) 7739 (9.0) 4204 (4.9) 8116 (9.3) 86 310 (20.3)
75-99 73 125 (74.1) 10 181 (10.3) 5250 (5.3) 10 170 (10.3) 98 726 (23.2)
Race
White 315 166 (77.3) 39 200 (9.6) 18 052 (4.4) 35 550 (8.7) 407 968 (95.8)
Black 1286 (51.8) 500 (20.1) 363 (14.6) 333 (13.5) 2482 (0.6)
Other 11 720 (75.8) 412 (2.7) 186 (1.2) 3147 (20.3) 15 465 (3.6)
Anatomic location
Head and neck 67 980 (77.6) 9140 (10.4) 2036 (2.3) 8405 (9.7) 87 561 (20.6)
Trunk 111 247 (81.3) 12 071 (8.8) 2817 (2.1) 10 754 (7.8) 136 889 (32.1)
Limbs 146 001 (81.5) 16 259 (9.1) 3314 (1.9) 13 561 (7.5) 179 135 (41.1)
Overlapping region or NOS 2014 (9.7) 2297 (11.0) 10 321 (49.6) 6191 (29.7) 20 823 (4.9)
Skin of genital organs 930 (61.7) 345 (22.9) 113 (7.5) 119 (7.9) 1507 (0.4)
Morphology
Malignant melanoma, NOS 156 892 (1.8) 17 992 (8.2) 14 538 (6.7) 29 031 (13.3) 225 635 (51.9)
Superficial spreading 115 022 (89.0) 7906 (6.1) 1077 (0.8) 5285 (4.1) 129 782 (29.8)
Lentigo maligna 23 590 (88.0) 808 (3.0) 162 (0.6) 2258 (8.4) 27 163 (6.2)
Nodular 19 161 (62.1) 8963 (29.1) 1653 (5.4) 1064 (3.4) 31 329 (7.2)
Acral lentiginous 2990 (68.2) 1017 (23.2) 189 (4.3) 186 (4.3) 4428 (1.0)
Others 10 517 (65.2) 3426 (21.2) 982 (6.1) 1206 (7.5) 16 518 (3.8)
Total 328 172 (77.1) 40 112 (9.4) 18 601 (4.4) 39 030 (9.1) 425 915 (100.0)
a NOS ¼ not otherwise specified; SEER ¼ Surveillance, Epidemiology, and End Results.
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44.8%) in 2001 to 56.1% (95% CI ¼ 54.6% to 57.6%) in 2013. Among
Blacks, 1-year survival improved from 37.0% (95% CI ¼ 32.0% to
42.7%) to 50.7% (95% CI ¼ 46.3% to 55.7%) over the same period.
The excess hazard of death because of melanoma within 1 year
of diagnosis was 13% higher in Blacks than Whites (excess haz-
ard ratio ¼ 1.13, 95% CI ¼ 1.00 to 1.27; data not shown).
Discussion
This study includes data from 34 state-wide cancer registries,
covering 56.9% of the US population and is the largest
population-based analysis to date of trends in 1-year survival
for distant-stage cutaneous melanoma. It shows a dramatic im-
provement in survival, particularly between 2010 and 2013.
The proportion of melanomas diagnosed at a distant stage
remained stable over time (4%-5%) and was slightly lower in
women than men. Sex inequalities in stage at diagnosis are well
known (20–22); they are commonly attributed to differences in
health-seeking behavior (23). Traditionally, women tend to visit
their health-care provider and perform skin checks more fre-
quently than men; this can translate to a higher proportion of
women being diagnosed with localized disease.
Blacks were more likely to be diagnosed with distant-stage
melanoma than Whites. The perception among African
Americans that melanoma risk is low is considered a major
cause for delayed diagnosis (24,25). Consistent with previous
studies (26–29), patients diagnosed at a distant stage were gen-
erally older.
One-year net survival improved noticeably for men and
women and in both Blacks and Whites. This improvement may
reflect the recent introduction of new treatments for metastatic
and unresectable disease.
The first immune checkpoint inhibitor approved by the FDA,
ipilimumab (30), in March 2011 showed 1-year overall survival
for patients diagnosed with metastatic melanoma in a phase III
randomized clinical trial as high as 45.6% compared with less
than 30% (25.3%) for patients treated with standard therapy (31).
Vemurafenib, the first licensed targeted treatment for
patients with metastatic disease and the BRAF V600E mutation,
was also shown to increase short-term survival. A phase III ran-
domized trial of 675 patients diagnosed with metastatic
melanoma showed an overall 6-month survival of 84% (95% CI
¼ 78% to 89%) in those treated with vemurafenib compared
with 64% (95% CI ¼ 56% to 73%) in those treated with dacarba-
zine (32). The FDA approved the drug on this evidence in August
2011 (33).
Our study has shown a substantial improvement in short-
term survival since 2010-2011 for patients diagnosed with
distant-stage melanoma of the skin, particularly for younger
patients. Most of the improvement occurred from 2010, one
year before FDA approval of the new lines of treatment. Some of
these patients may have been recruited to clinical trials, which
started well before 2010 (31,34–36). Additionally, they may have
received the newer treatments through the FDA expanded ac-
cess programs (37), which provide access to investigational
drugs before their official approval to patients with life-
threatening conditions who cannot be enrolled in clinical trials.
Data on whether the patients were recruited to a clinical trial
or received systemic therapy for compassionate use were not
available to us to explore these hypotheses. However, a
population-based study of the impact of targeted and immune-
based therapies for metastatic or unresectable melanoma in
Ontario found that about 5% of patients were already being
treated with the new therapies in 2007; this percentage in-
creased to more than 82% by 2015 (38). That study confirmed
the use of immunotherapy well before the approval of ipilimu-
mab by Health Canada in 2012 and highlighted its widespread
use in recent years. A similar study in the United States showed
that the use of immunotherapy in patients younger than
65 years improved rapidly after 2010, from 8-12% during 2004-
2010 to 30% in 2014 (39).
Patients aged 75 years or older with distant-stage disease ex-
perienced considerably less improvement in short-term sur-
vival. This may be due to less frequent use of the newer
therapies. A recent study designed to identify factors associated
with the treatment of metastatic melanoma in the United
States (40) found that older patients were less likely to receive
ipilimumab or to be tested for the BRAF mutation. This may
have resulted from concerns about how they would tolerate the
new treatments. Previous studies on solid tumors have shown
that age can act as a barrier to receipt of optimal treatment be-
cause of a higher prevalence of comorbidity or absence of data
on treatment efficacy from clinical trials and more frequent ad-
verse effects (41,42). A US study showed that only 46% of
patients aged 80 years or older received imatinib, a highly effec-
tive treatment for chronic myeloid leukaemia, compared with
89.7% of those aged 20-59 years (43).
The CONCORD-3 study protocol did not require detailed in-
formation on specific types of treatment, so it was not possible
to estimate the proportion of patients who received immune-
checkpoint inhibitors or targeted treatments. Data on socio-
economic status and type of health insurance were not
collected. That information might have helped to explain the
disparities in the stage distribution and stage-specific survival
by age and race. An analysis of 61 650 melanoma patients aged
18-64 years diagnosed in the United States during 2007-2012 es-
timated that the proportion of patients with metastatic disease
ranged from only 3.7% in the non-Medicaid insurance group to
15.5% among Medicaid and 10.7% among uninsured
patients (44). A recent systematic review of the cost-
effectiveness of immune-checkpoint inhibitors in the United
States estimated that the individual cost of treatment for meta-
static melanoma ranged from US$152 000 to US$303 000 for a
patient with a median survival time (45). The cost of targeted
therapies for metastatic melanoma with the BRAF V600E
Figure 1. Patients included in survival analysis.
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mutation was estimated at between US$149 000 and US$319 000
(46). Recent analyses have shown that patients were less likely
to receive immunotherapy if they had no insurance or only
Medicaid coverage, received a lower income, or received care at
a community practice rather than an academic center
(39,47,48). Such differences in access to treatment may partly
explain the racial disparities in the recent trends in short-term
survival reported in this study.
One-year net survival was consistently lower in Blacks than
Whites. Survival was not estimated for other races. The
Figure 2. Trends in age-specific 1-year net survival (%) for patients diagnosed with distant-stage cutaneous melanoma during 2001-2013 in the United States.
Figure 3. Trends in age-standardized 1-year net survival (%) for patients diagnosed with distant-stage cutaneous melanoma during 2001-2013 in the United States, by
race.
V. Di Carlo et al. | 7 of 9
proportion of patients lost to follow-up, including those whose
deaths are missed by the cancer registries, is generally higher
among Asians or Pacific Islanders than Whites and Blacks
(49,50). Incomplete follow-up among Asians or Pacific Islanders
and other minority groups may lead to overestimation of sur-
vival and biased comparisons.
Several studies have shown a survival disadvantage for
Blacks diagnosed with melanoma in the United States. A study
of more than 260 000 people diagnosed during 1988-2011 esti-
mated an absolute gap of almost 20% (89% vs 70%) between
Blacks and Whites in 5-year relative survival for all stages com-
bined (26). Among Whites and Blacks of non-Hispanic origin,
the difference in 5-year overall survival was almost 30% (82% vs
53%) during 1982-2011 (27).
Racial disparities in survival from melanoma have commonly
been ascribed to a less favorable stage distribution of Black
patients (26,51–53). However, we have shown that the proportion
of distant-stage melanoma was higher among Blacks than
Whites, and 1-year survival for distant-stage melanoma was con-
sistently lower among Blacks than among Whites. This gap in sur-
vival suggests racial differences in treatment and access to care.
Despite the exclusion of about 2500 patients registered with
a distant-stage melanoma in cancer registries for which inci-
dence data were not complete for 2001-2013, we were neverthe-
less able to include 18 601 patients: this, to our knowledge, is
the largest population-based analysis of trends in 1-year net
survival for distant-stage disease.
In conclusion, to our knowledge, this is the first population-
based study to show a recent improvement in short-term survival
from distant-stage cutaneous melanoma in the United States.
This may be due to the availability of new and more effective
therapies for the treatment of metastatic or unresectable disease.
The dramatic improvement since 2010 in short-term survival for
melanoma of the skin diagnosed at the metastatic or unresect-
able stage is important, because for most other solid tumors, sur-
vival for metastatic disease has not changed for several decades
(54–56). More detailed population-based studies would help evalu-
ate access to novel treatments and their longer term survival ben-
efit for patients diagnosed with distant-stage melanoma.
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